Given the up-regulation of STING expression induced by the SGLT2 inhibitor, we also found that the combined treatment with SGLT2 inhibitor and 2’3’-cGAMP further promoted the infiltration of CD4+ and CD8+ T cells, exerting synergistic antitumor effects in osteosarcoma. The gene discussed is STING1; the disease is osteosarcoma.